NFE2L2 and cardiomyopathy: Mechanistically, treatment with DOX led to cardiomyopathy through the accumulation of nonheme iron via heme degradation in response to Nrf2-associated upregulation of HMOX1, which can be rescued by HMOX1 antagonists or in Nrf2-deficient mice [37].